Acronyme du projet/ Acronym of the project

4.1.6.2Valorisation / Exploitation of results

LIST/Nano has issued 14 patents during the last 5 years (full list in 7.2). Besides, 11 direct contracts have been signed or are still alive between the LIST/Nano team and industrial companies (including Tracetel, SGN, Jessica, Sbibi, Photonis, Cerca, NovaSic, BioMerieux, AsuLab..). 9 other collaborations exist through funded scientific projects.

A technological transfer concerning diamond-based dosimeters for radiotherapy is currently under way.

For all its valorization activities, LIST/Nano relies on the IP pool at CEA/DRT

4.1.6.3Enseignement superieur / Higher education

Several LIST/Nano scientists are involved in higher education, together with communication activities towards the society and young students.

• PhD level: 2 of us have the HdR and commonly act as Thesis Director

• Master Level: courses are given at the master MATEC (UVSQ)

• UnderGrad level: regular teaching at Undergrad level (U. Paris XI,

• High School and colleges: We are regularly involved in educational events in high schools, such as the CAMS project (Accompanying high school students towards science jobs), tutoring students for personal projects

• Numerous courses have been given by our scientists in CNRS thematic schools

• Nano events:

• 
  Cyclope Junior conference: "Researchers grow diamonds!" targeted for the 12 to 18 years old teenagers ", June 2007.
  
• 
  frequent location of interest for scientific conferences and guided tours for VIP (e.g. "Quintésciences Expérimentales " or "Olympiades de la Physique" contests laureates, scientific documentary and scientific movies directorsCEA/INST formation for researchers, "NANO: objets et technologies" (2007 et 2009)
  

4.1.6.4Organisation / Organisation

LIST/Nano belongs to the LIST institute. Its organization is typical of Research & Technology Organisation: strategy driven by Intellectual Property generation for valorisation (technology transfer and patent generation). LIST/Nano is essentially funded by contracts. It is able to obtain through industrial transfer and calls from different agencies at the local (C'Nano), national (ANR, FUI) or international (EU) levels. During the last 3 years, 12 ANR contracts and 7 EU ones were obtained by LIST/Nano researchers, many of them involving industrial partners.

4.1.7Partenaire 7/ Partner 7 : Laboratoire de Physico-Chimie, Pharmacotechnie, Biopharmacie (PCPB) UMR8612

4.1.7.1Recherche et innovation / Research and innovation

The Laboratoire of "Physico-Chimie, Pharmacotechnie et Biopharmacie" (LPCPB; UMR 8612) consists of two teams presently located at Châtenay-Malabry, but intended to move soon to the new NanoSciences Research Center called NanoINNOV-C2N. In a few years, that center will gather in a single location ca. 30% of the scientists of the NanoSaclay LabEx. Moving those two CNRS-U. Paris XI teams are thus the first step to the constitution of a strong and highly visible LabEx.

The two teams are named "Nouvelles stratégies de ciblage appliquées au cancer et aux maladies du système nerveux central" (Head Pr P. Couvreur) and " Protéines et Nanotechnologies en Sciences Séparatives" (Head Pr. M. Taverna). Both teams focus their efforts on (i) the conception and on the development of nanocarriers for the administration, the transport and the tissue/cell targeting of drugs and (ii) the chemical functionalization of nanoparticules by antibodies or other biological molecules. The research performed intends to elaborate new treatments towards severe diseases (ie. cancer, neurodegenerative diseases, intracellular infections etc.). Overcoming resistance mechanisms by using drug nanocarriers is another important challenge of the research team as well as the conception of « Nanotheranostics » (ie. nanoparticles possessing a double functionality: Therapeutic and imaging).

The LPCPB gathers 3 researchers, 9 teaching researchers, 1 research engineer, 13 PhD students and 8 postdoctoral fellows.
Evaluation: Both teams were already evaluated by AERES, in 2008. Their quotation was A+

Excerpt of the report: "Un très grand nombre de publications dans les meilleures revues du domaine (Small, NanoLett, JACS) traduit l'activité scientifique remarquable de cette équipe qui par ailleurs coordonne deux projets ANR. Son rayonnement international a été concrétisé par la remise de deux prix prestigieux, un nombre important de conférences invitées dans des congrès internationaux et l'accueil de plusieurs doctorants étrangers. La prise de 7 brevets, la création de deux start-up et l'établissement de nombreuses collaborations industrielles témoignent du dynamisme de cette équipe vers le monde socio-économique. Cette équipe, et le laboratoire qui l’héberge, sont des références internationales dans le domaine de la pharmacie galénique dans ce qu’elle a d’innovant. Elle contribue efficacement à la diffusion des connaissances et à l’appui des politiques publiques. L'arrivée de deux nouveaux membres en 2005 (Pr) et 2007 (CR) prouve la vitalité excellente de cette équipe et sa vision de l'avenir. Le choix des nouvelles compétences relève d'une volonté stratégique de renforcer le caractère scientifique rationnel des approches de l'équipe, en adéquation avec les projets, ce qui ne peut être que très positif pour le futur."

High profile scientists:
COUVREUR, Patrick (H = 57, 11,000 citations) ; U. Paris XI, Pr High Class

Distinctions: senior member at the Institut Universitaire de France (IUF), ERC Advanced Grant (2010-2015); Best Innovative Company Award in 2006 and 2009; Host Madsen Medal 2007;  Marie-Maurice Janot Lecture Award 2008; GALIEN prize 2009; Innovation Award from l'Usine Nouvelle (2008) and the Hauts de Seine District (2006)

Major publications (IF>7): 1 Nature Mater., 3 JACS, 1 Adv. Funct. Mater., 1 NanoLett., 1 J. NeuroSci. , 1 Angew. Chem., 1 Adv. Drug Deliver.

Other assessment points : Professor at the prestigious "Collège de France (holder of the chair “Innovations Technologiques 2009-2010); Member of the "Académie des Technologies"; Member of the "Académie de Pharmacie"; Corresponding Member of the "Académie de Médecine"; Foreign Member of the "Académie Royale de Médecine" of Belgium; Member of the "Senate" of the European Federation of Pharmaceutical Sciences (EUFEPS)
GREF Ruxandra (H = 29, 4.000 citations): CNRS, DR2

Distinctions: Innovation Award, U. Paris XI (2004); Best paper Award, Eur. J. Pharm. Biopharm. (2001)

Major publications (IF>7):1 Science, 1 Nature Mater., 1 Adv. Drug Deliv., 1 Angew. Chem., A Adv. Funct. Mater.
DUBERNET, Catherine (H=24, 2111 citations): U. Paris XI, Pr 1st class

Distinctions: Chevalier dans l’ordre des Palmes académiques (2009)

Major publications (IF>7): 1 JACS, 1 Nano Lett.

Other assessment points: Vice-President of U. Paris XI (in charge of evaluation) 
SMADJA, Claire (H = 14, > 800 citations): U. Paris XI MC, HDR

Major publications (IF>7): 1 PNAS, 1 Embo J, 2 J Neurosci.

Other assesment points: member of the scientific committee of the university Paris XI., 2 papers cited more than 100 times, coordinator of 1 C’nano project (Cantiprote, 2010)
Research activities: The two teams at LPCPB issued 126 publications in reviewed journals between 2006 and 2010, together with 9 patents. Among those publications: 1 Nature Mater., 1 Angew. Chem. Inter. Ed., 1 NanoLett., 3 JACS, 1 Adv. Funct. Mater., 2 J. NeuroSci., 1 Adv. Drug Deliv.(see 7.2 for details)

15 PhD theses have been obtained within the same period. Among them, 12 new doctors already hold a permanent position and 2 hold a temporary position. 3 HdR were obtained during that period at LPCPB.

Scientists from LPCPB are given more than 25 invited lectures at national and international conferences, including for delivering keynote lectures. (A partial list is given in 7.2)

LPCPB teams have numerous collaborations both within the Campus Paris-Saclay (some of them members of the NanoSaclay LabEx), with many research French labs and more than 25 international active collaborations)

Equipments: As both teams will move to the NanoINNOV location, a large part of the equipment will have to be purchased from the NanoSaclay LabEx funding. But some part of the actual equipment will follow the move, including:

• 
  Small animal experiments platform and cell culture facilities.
  
• 
  Beta-imager and microfluidics apparatus (already purchased from private grants)
  
• 
  Small lab equipment (capillary electrophoresis, lab on chip (2), microscopy, spectrofluorimeter, microplate titer, conventional gel electrophoresis, HPLC, centrifugators..)
  

The LPCPB is partner with the IRT SystemX, through the NanoBio et NanoMedicine program, with the Institute of analytical and biological sciences “ISAB” recently created and applies for a grant at the “Nanobiotechnologie project” of the “Investissement d’Avenir” program